5.05
price up icon2.02%   0.10
pre-market  Pre-mercato:  5.22   0.17   +3.37%
loading

Immix Biopharma Inc Borsa (IMMX) Ultime notizie

pulisher
Jan 02, 2026

Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn

Jan 02, 2026
pulisher
Dec 31, 2025

Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn

Dec 31, 2025
pulisher
Dec 31, 2025

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat

Dec 31, 2025
pulisher
Dec 29, 2025

Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World

Dec 29, 2025
pulisher
Dec 22, 2025

Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN

Dec 22, 2025
pulisher
Dec 21, 2025

Is Immix Biopharma Inc. stock positioned well for digital economyLong Setup & Fast Exit and Entry Strategy Plans - Улправда

Dec 21, 2025
pulisher
Dec 20, 2025

Immix Biopharma (IMMX) Price Target Increased by 50.00% to 12.24 - Nasdaq

Dec 20, 2025
pulisher
Dec 20, 2025

Is Immix Biopharma Inc. stock resilient to inflation2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Why Immix Biopharma Inc. stock remains on buy listsPortfolio Return Report & Precise Swing Trade Entry Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Why Immix Biopharma Inc. stock remains undervaluedJuly 2025 Outlook & High Return Stock Watch Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

What momentum indicators show for Immix Biopharma Inc. stock2025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Is Immix Biopharma Inc. stock positioned for long term growth2025 Retail Activity & Free Risk Controlled Daily Trade Plans - DonanımHaber

Dec 19, 2025
pulisher
Dec 18, 2025

What hedge fund activity signals for Immix Biopharma Inc. stock2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru

Dec 18, 2025
pulisher
Dec 13, 2025

Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World

Dec 13, 2025
pulisher
Dec 12, 2025

Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in

Dec 12, 2025
pulisher
Dec 12, 2025

Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in

Dec 12, 2025
pulisher
Dec 12, 2025

Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World

Dec 12, 2025
pulisher
Dec 11, 2025

Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn

Dec 11, 2025
pulisher
Dec 11, 2025

FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat

Dec 11, 2025
pulisher
Dec 11, 2025

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha

Dec 11, 2025
pulisher
Dec 10, 2025

Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis

Dec 10, 2025
pulisher
Dec 10, 2025

Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada

Dec 10, 2025
pulisher
Dec 10, 2025

Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada

Dec 10, 2025
pulisher
Dec 10, 2025

Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com

Dec 10, 2025
pulisher
Dec 10, 2025

Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com

Dec 10, 2025
pulisher
Dec 10, 2025

Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia

Dec 10, 2025
pulisher
Dec 10, 2025

Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 10, 2025
pulisher
Dec 10, 2025

IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus

Dec 10, 2025
pulisher
Dec 09, 2025

Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma closes $93.7 million public offering - Investing.com

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN

Dec 09, 2025
pulisher
Dec 09, 2025

Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com

Dec 09, 2025
pulisher
Dec 09, 2025

Immix Biopharma — Promising NEXICART-2 data; runway extended - Smartkarma

Dec 09, 2025
pulisher
Dec 08, 2025

Immix Biopharma Enters Underwriting Agreement with Morgan Stanley - TipRanks

Dec 08, 2025
pulisher
Dec 08, 2025

Form 424B5 Immix Biopharma, Inc. - StreetInsider

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Biopharma’s Market Dynamics Amid Economic Shifts - timothysykes.com

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Biopharma Prices $100 Million Offering - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Biopharma Announces Positive Phase 2 Trial Results - TipRanks

Dec 08, 2025
pulisher
Dec 08, 2025

Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc. - StreetInsider

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView — Track All Markets

Dec 08, 2025
pulisher
Dec 08, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - The Manila Times

Dec 08, 2025
pulisher
Dec 08, 2025

Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug - Investing.com Nigeria

Dec 08, 2025
$102.71
price up icon 28.63%
$33.90
price up icon 2.42%
$110.57
price up icon 3.67%
$100.08
price up icon 2.03%
biotechnology ONC
$333.87
price up icon 4.22%
$176.00
price up icon 0.53%
Capitalizzazione:     |  Volume (24 ore):